NUK - logo
E-resources
Full text
Peer reviewed
  • Binimetinib versus dacarbaz...
    Dummer, Reinhard, Prof; Schadendorf, Dirk, Prof; Ascierto, Paolo A, MD; Arance, Ana, MD; Dutriaux, Caroline, MD; Di Giacomo, Anna Maria, MD; Rutkowski, Piotr, Prof; Del Vecchio, Michele, MD; Gutzmer, Ralf, Prof; Mandala, Mario, MD; Thomas, Luc, Prof; Demidov, Lev, Prof; Garbe, Claus, Prof; Hogg, David, MD; Liszkay, Gabriella, Prof; Queirolo, Paola, MD; Wasserman, Ernesto, MD; Ford, James, MS; Weill, Marine, MSc; Sirulnik, L Andres, MD; Jehl, Valentine, MSc; Bozón, Viviana, MD; Long, Georgina V, Prof; Flaherty, Keith, MD

    The lancet oncology, 04/2017, Volume: 18, Issue: 4
    Journal Article

    Summary Background There are no established therapies specific for NRAS -mutant melanoma despite the emergence of immunotherapy. We aimed to assess the efficacy and safety of the MEK inhibitor binimetinib versus that of dacarbazine in patients with advanced NRAS -mutant melanoma. Methods NEMO is an ongoing, randomised, open-label phase 3 study done at 118 hospitals in 26 countries. Patients with advanced, unresectable, American Joint Committee on Cancer stage IIIC or stage IV NRAS -mutant melanoma who were previously untreated or had progressed on or after previous immunotherapy were randomised (2:1) to receive either binimetinib 45 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Randomisation was stratified by stage, performance status, and previous immunotherapy. The primary endpoint was progression-free survival assessed by blinded central review in the intention-to-treat population. Safety analyses were done in the safety population, consisting of all patients who received at least one study drug dose and one post-baseline safety assessment. This study is registered with ClinicalTrials.gov , number NCT01763164 and with EudraCT, number 2012-003593-51. Findings Between Aug 19, 2013, and April 28, 2015, 402 patients were enrolled and randomly assigned, 269 to binimetinib and 133 to dacarbazine. Median follow-up was 1·7 months (IQR 1·4–4·1). Median progression-free survival was 2·8 months (95% CI 2·8–3·6) in the binimetinib group and 1·5 months (1·5–1·7) in the dacarbazine group (hazard ratio 0·62 95% CI 0·47–0·80; one-sided p<0·001). Grade 3–4 adverse events seen in at least 5% of patients the safety population in either group were increased creatine phosphokinase (52 19% of 269 patients in the binimetinib group vs none of 114 in the dacarbazine group), hypertension (20 7% vs two 2%), anaemia (five 2% vs six 5%), and neutropenia (two 1% vs ten 9%). Serious adverse events (all grades) occurred in 91 (34%) patients in the binimetinib group and 25 (22%) patients in the dacarbazine group. Interpretation Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS -mutant melanoma after failure of immunotherapy. Funding Array BioPharma and Novartis Pharmaceuticals Corporation.